Vesselon
Norwalk, US · Founded 2012 · Delaware corporation
Founders & leadership
RL
Rhodemann LiExecutive
CT
Clayton T LarsenPresident and Chief Executive Officer; Director
CL
Clay LarsenPresident and Chief Executive Officer; Director
Board
KK
Kevin KimberlinBoard director
PS
Paul S. Latchford, Jr.Board director
JR
Jurgen RathsBoard director
JC
Jon C SerbousekBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 4 rounds · 2014–2016
▶$250KraisedAug 2016 · 3 investors · BiotechnologyRule 506(b)
▶$250KraisedAug 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rhodemann LiExecutive Officer, Director
- Jon SerbousekDirector
- Paul LatchfordDirector
- Jurgen RathsDirector
- Clay LarsenExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- Minimum investment
- $25K
- Proceeds to insiders
- $100K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$75KraisedJul 2016 · 1 investors · BiotechnologyRule 506(b)
▶$75KraisedJul 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LatchfordDirector
- Jon SerbousekDirector
- Rhodemann LiExecutive Officer, Director
- Jurgen RathsDirector
- Clay LarsenExecutive Officer, Director
- Offering amount
- $150K
- Amount sold
- $75K
- Minimum investment
- $75K
- Proceeds to insiders
- $30K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1MraisedJun 2015 · 11 investors · BiotechnologyRule 506(c)
▶$1MraisedJun 2015 · 11 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Paul S. Latchford, Jr.Director
- Jurgen RathsDirector
- Rhodemann LiExecutive Officer, Director
- Clayton T LarsenExecutive Officer, Director
- Jon C SerbousekDirector
- Offering amount
- $4M
- Amount sold
- $1M
- Minimum investment
- $50K
- Sales commissions
- $33.2K
- Proceeds to insiders
- $112K
- Placement agents
- Spencer Trask Ventures, Inc.
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
▶$100KraisedJul 2014 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedJul 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clay LarsenExecutive Officer, Director
- Rhodemann LiExecutive Officer, Director
- Kevin KimberlinDirector
- Offering amount
- $200K
- Amount sold
- $100K
- Minimum investment
- $50K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Verseon5 shared keywordsVerseon uses quantum physics-based modeling combined with AI to design novel small-molecule drug candidates for major human diseases. Its pipeline targets conditions including cardiovascular disease (anticoagulants), diabetic vision loss, multidrug-resistant cancers, and solid-tumor metastasis, with candidates ranging from preclinical to clinical stages.
Regeneron NASDAQ: REGN www.regeneron.com5 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Dendreon NASDAQ: DNDN www.dendreon.com4 shared keywordsDendreon develops and manufactures cellular immunotherapies, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for prostate cancer patients. The company also provides cell therapy research, development, and contract manufacturing services to other companies bringing cellular therapies to market.
Lexicon Pharmaceuticals4 shared keywords
Geron3 shared keywordsGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
Novoron3 shared keywordsNovoron develops lipoprotein-receptor small molecule therapies aimed at repairing damage and degeneration of the brain and spinal cord, including treatments for proteinopathies and neuroregeneration following traumatic injury. The company focuses on drug discovery for neurological conditions such as neurodegeneration and cognitive decline.
Companies competing with Vesselon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- How much funding has Vesselon raised?
- Vesselon has disclosed $1.4M raised across 4 rounds.
- Where is Vesselon headquartered?
- Vesselon is headquartered in Norwalk, US.